OTCMYECO
Market cap1mUSD
Dec 13, Last price
0.14USD
Name
Yulong Eco-Materials Ltd
Chart & Performance
P/E
—
P/S
21.06
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
33.50%
Rev. gr., 5y
-65.12%
Revenues
49k
Net income
-1m
L-93.98%
CFO
-3m
L-84.25%
Profile
EV Biologics, Inc., a biotechnology company, engages in the commercial development of extracellular vesicles (EVs) as biological modalities for diagnostics and therapeutics. It is involved in developing vaccines, therapeutics, and cures based on its proprietary multifunctional EV platform. The company also focuses on developing human mesenchymal and other stem cell, and cell-derived products to market in the cosmetic and biopharmaceutical spaces. The company was formerly known as Yulong Eco-Materials Limited and changed its name to EV Biologics, Inc. in August 2020. EV Biologics, Inc. was incorporated in 2011 and is headquartered in Cheyenne, Wyoming.
IPO date
Jun 29, 2015
Employees
284
Domiciled in
CN
Incorporated in
KY
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2017‑12 | 2016‑06 | 2015‑06 | |
| Income | ||||||||
Revenues | 49 | 119 | ||||||
Cost of revenue | ||||||||
Unusual Expense (Income) | ||||||||
NOPBT | 49 | 119 | ||||||
NOPBT Margin | 100.00% | 100.00% | ||||||
Operating Taxes | (168) | (228) | (237) | |||||
Tax Rate | ||||||||
NOPAT | 217 | 228 | 355 | |||||
Net income | (1,267) -93.98% | (21,055) 5,330.79% | (388) 291.77% | |||||
Dividends | ||||||||
Dividend yield | ||||||||
Proceeds from repurchase of equity | ||||||||
BB yield | ||||||||
| Debt | ||||||||
Debt current | 1,495 | 22,676 | 21,680 | |||||
Long-term debt | ||||||||
Deferred revenue | ||||||||
Other long-term liabilities | ||||||||
Net debt | 1,368 | 22,341 | 18,670 | |||||
| Cash flow | ||||||||
Cash from operating activities | (3,283) | (20,841) | 698 | |||||
CAPEX | (39) | (19,266) | ||||||
Cash from investing activities | 10,799 | 19,784 | (21,676) | |||||
Cash from financing activities | (7,724) | 1,993 | 21,680 | |||||
FCF | (1,590) | 7,437 | 746 | |||||
| Balance | ||||||||
Cash | 127 | 335 | 600 | |||||
Long term investments | 2,410 | |||||||
Excess cash | 124 | 335 | 3,004 | |||||
Stockholders' equity | (45,390) | (54,543) | (33,494) | |||||
Invested Capital | 45,201 | 63,385 | 62,390 | |||||
ROIC | 0.40% | 0.36% | 0.69% | |||||
ROCE | 0.41% | |||||||
| EV | ||||||||
Common stock shares outstanding | 10,225 | 7,225 | 7,225 | |||||
Price | 1.70 109.88% | 0.81 -83.80% | ||||||
Market cap | 12,283 109.88% | 5,853 -83.80% | ||||||
EV | 34,624 | 24,523 | ||||||
EBITDA | 49 | 119 | ||||||
EV/EBITDA | 206.25 | |||||||
Interest | ||||||||
Interest/NOPBT | ||||||||